Diabetes
-
New Startup Launches To Bring VBC to Endocrinology Practices
Valendo Health, the newest startup built at Redesign Health, launched on Tuesday. The company partners with independent endocrinology practices and provides technology to help them thrive in value-based care arrangements.
-
Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking
Insulin prices have long been a pain point for diabetics. The big three insulin manufacturers have cut prices across their product lineups, but potential competition from other biosimilar insulins is still in earlier stages of development.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Why Omada’s CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program
Amazon launched a new initiative to help connect people to digital health benefits that they may not know are available to them. Omada Health is its first partner. CEO Sean Duffy said his company stood out from the many other virtual diabetes care companies out there because about 20 million Americans — many of whom shop on Amazon — are eligible for Omada’s programs.
-
Devices & Diagnostics, Artificial Intelligence
Medtronic CEO On the Company’s AI: This Isn’t About ChatGPT
Geoff Martha sought to establish a clear line between popular understanding of AI created by apps like ChatGPT and what he believes is the significant impact that Medtronic’s AI-enabled products are already having on patients and other healthcare stakeholders today.
-
NEBGH Helps Employers Combat Cardiovascular Disease in Women Through New Guide
A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.
-
Eli Lilly Plans New $2.5B Manufacturing Site in Germany for Injectable Meds
The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline
AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.
-
BioPharma, Consumer / Employer, Pharmacy
Walgreens Exec: Reimbursement Models Need to Catch Up with GLP-1 Demand
Walgreens is seeing “an enormous amount of demand” for injectable weight loss drugs, its president of U.S. healthcare said during the Reuters Total Health conference in Chicago. He declared that the healthcare industry needs to come up with a reimbursement model “that correctly compensates pharmacists and others” to administer these drugs. In his view, reimbursement hasn’t caught up with the demand.
-
FDA Approves Eli Lilly Weight Drug, Now Set to Compete Against Novo’s Wegovy
Eli Lilly weight management drug Zepbound landed its much anticipated FDA approval. The new Lilly product is in the same drug class as Novo Nordisk weight medication Wegovy, but it offers an additional mechanism of action and costs less.
-
Devices & Diagnostics, Health Tech
Abbott-Bigfoot Deal Proves That Diabetes Is a Hot Area for Digital Health Investment
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
-
Consumer / Employer, Health Tech
Amazon’s Automatic Coupons for Diabetes Products While “Incremental” Will Still Be a “Gamechanger,” Experts Say
Amazon Pharmacy announced Tuesday that it is launching automatic coupons for more than 15 insulin and diabetes care brands. The move, while incremental, solves a major pain point for consumers with diabetes, as many struggle to afford insulin products.